These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7572468)

  • 21. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
    Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
    Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactivation of murine latent HSV infection by epinephrine iontophoresis.
    Willey DE; Trousdale MD; Nesburn AB
    Invest Ophthalmol Vis Sci; 1984 Aug; 25(8):945-50. PubMed ID: 6086546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes.
    Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO
    FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate and acquired immunity to herpes simplex virus type 1.
    Halford WP; Veress LA; Gebhardt BM; Carr DJ
    Virology; 1997 Sep; 236(2):328-37. PubMed ID: 9325240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV.
    Sanna PP; De Logu A; Williamson RA; Hom YL; Straus SE; Bloom FE; Burton DR
    Virology; 1996 Jan; 215(1):101-6. PubMed ID: 8553581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative studies on activation of latent herpes simplex virus in rabbits.
    Kocisová M; Rajcáni J; Szántó J
    Acta Virol; 1985 Sep; 29(5):373-85. PubMed ID: 2866691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced protection against HSV lethal challenges in mice by immunization with a combined HSV-1 glycoprotein B:H:L gene DNAs.
    Cha SC; Kim YS; Cho JK; Cho J; Kim SY; Kang H; Cho MH; Lee HH
    Virus Res; 2002 Jun; 86(1-2):21-31. PubMed ID: 12076826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spread of HSV and establishment of latency after corneal infection in inbred mice.
    Abghari SZ; Stulting RD; Nigida SM; Downer DN; Nahmias AJ
    Invest Ophthalmol Vis Sci; 1986 Jan; 27(1):77-82. PubMed ID: 3000975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Herpes simplex virus subunit vaccine: characterization of the virus strain used and testing of the vaccine.
    Hilfenhaus J; Moser H; Herrmann A; Mauler R
    Dev Biol Stand; 1982; 52():321-31. PubMed ID: 6299841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
    Augustinova H; Hoeller D; Yao F
    J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
    Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
    J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
    Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenicity and latency competence for rabbits of the herpes simplex virus type 1 ANGpath gC and gE defective mutants.
    Kúdelová M; Kostál M; Cervenáková L; Rajcáni J; Kaerner HC
    Acta Virol; 1991 Sep; 35(5):438-49. PubMed ID: 1688077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of ocular herpes simplex virus shedding by iontophoresis of epinephrine into rabbit cornea.
    Kwon BS; Gangarosa LP; Burch KD; deBack J; Hill JM
    Invest Ophthalmol Vis Sci; 1981 Sep; 21(3):442-9. PubMed ID: 6268564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Herpes simplex virus recovery in neural tissues after ocular HSV shedding induced by epinephrine iontophoresis to the rabbit cornea.
    Hill JM; Kwon BS; Shimomura Y; Colborn GL; Yaghmai F; Gangarosa LP
    Invest Ophthalmol Vis Sci; 1983 Feb; 24(2):243-7. PubMed ID: 6298139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.
    Dalai SK; Pesnicak L; Miller GF; Straus SE
    J Neurovirol; 2002 Feb; 8(1):35-44. PubMed ID: 11847590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.
    Geiss BJ; Smith TJ; Leib DA; Morrison LA
    J Virol; 2000 Dec; 74(23):11137-44. PubMed ID: 11070010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HSV-1 shedding by lontophoresis of 6-hydroxydopamine followed by topical epinephrine.
    Shimomura Y; Gangarosa LP; Kataoka M; Hill JM
    Invest Ophthalmol Vis Sci; 1983 Dec; 24(12):1588-94. PubMed ID: 6418684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.